AltheRx is Granted U.S. Patent for Use of Solabegron in Combination With Antimuscarinics for the Treatment of Overactive Bladder
10/17/2013 10:13:35 AM
EXTON, Pa.--(BUSINESS WIRE)--AltheRx Pharmaceuticals, a privately-held clinical development company, today announced the United States Patent and Trademark Office issued a Notice of Allowance for the company’s U.S. Patent Application claiming a method of use for solabegron, a beta 3-adrenergic receptor agonist, in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB). Upon issuance, the patent will provide AltheRx a strong position through the early 2030s.
Help employers find you! Check out all the jobs and post your resume.
comments powered by